GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Liabilities-to-Assets

Amryt Pharma (Amryt Pharma) Liabilities-to-Assets : 0.56 (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Amryt Pharma's Total Liabilities for the quarter that ended in Sep. 2022 was $412.6 Mil. Amryt Pharma's Total Assets for the quarter that ended in Sep. 2022 was $736.9 Mil. Therefore, Amryt Pharma's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2022 was 0.56.


Amryt Pharma Liabilities-to-Assets Historical Data

The historical data trend for Amryt Pharma's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Liabilities-to-Assets Chart

Amryt Pharma Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 1.05 0.75 0.88 0.56

Amryt Pharma Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.56 0.56 0.55 0.56

Competitive Comparison of Amryt Pharma's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amryt Pharma's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Liabilities-to-Assets falls into.



Amryt Pharma Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Amryt Pharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Liabilities-to-Assets (A: Dec. 2021 )=Total Liabilities/Total Assets
=459.396/816.057
=0.56

Amryt Pharma's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2022 is calculated as

Liabilities-to-Assets (Q: Sep. 2022 )=Total Liabilities/Total Assets
=412.598/736.875
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amryt Pharma  (NAS:AMYT) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Amryt Pharma Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Amryt Pharma (Amryt Pharma) Business Description

Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).